Literature DB >> 12883804

[Reconstruction of the inferior vena cava for extended resection of malignant tumors].

D Grotemeyer1, M Pillny, B Luther, V Müller-Mattheis, S Ernst, W Sandmann.   

Abstract

OBJECTIVES: Malignant tumor invasion in the inferior vena cava (IVC) has for a long time been the limiting factor in the resection of retroperitoneal tumors. The clinical outcome in these patients depends on vascular surgical techniques, the central role of which is played by IVC reconstruction.
METHODS: Within the last 7 years, 9,085 vascular reconstructive procedures were performed in our department. Six patients suffered from retroperitoneal invasion of tumor into the IVC. After tumor resection, the involved IVC segments were replaced by polytetrafluorethylene (PTFE) grafts to restore IVC continuity. In three patients, an adjunctive arteriovenous (AV) fistula was constructed.
RESULTS: The graft patency after a mean follow-up of 30.2 months (range 1 to 79) was 83.3%. The only graft occlusion occurred in a patient without AV fistula. There were no perioperative deaths and no major complications demanding reoperation.
CONCLUSION: In patients with tumor involvement of the IVC, clinical outcome depends on vascular surgical coprocedure. After resection of the IVC, a PTFE graft should be interposed in combination with an AV fistula. Anticoagulation and CT scan are recommended after 3 months before ligation of the AV fistula.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883804     DOI: 10.1007/s00104-003-0632-8

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  2 in total

Review 1.  [Vascular replacement in abdominal tumor surgery].

Authors:  A Mehrabi; P Houben; N Attigah; D Böckler; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2011-10       Impact factor: 0.955

2.  [Interdisciplinary operative procedure-pelvis and abdomen].

Authors:  W Sandmann; K Grabitz; B Luther; B T Müller; T Pfeiffer
Journal:  Chirurg       Date:  2004-04       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.